Carregant...
Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children
Rituximab, a chimeric anti-CD20 monoclonal antibody originally licensed for lymphoma, is emerging as a novel steroid-sparing agent for idiopathic nephrotic syndrome in children. The potential use of anti-CD20 monoclonal antibodies in idiopathic nephrotic syndrome has contributed to shifting the view...
Guardat en:
| Publicat a: | Clin J Am Soc Nephrol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Nephrology
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4822672/ https://ncbi.nlm.nih.gov/pubmed/26585985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08500815 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|